Aeglea is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to address rare and other high burden diseases with unmet medical need. Aeglea’s lead product candidate, pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. Aeglea has an active discovery platform with programs for Homocystinuria and Cystinuria. The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Company’s Clinical Trials Application (CTA) for Homocystinuria and the Company is working to initiate a Phase 1/2 trial in the second quarter of 2020.
Data Provided by Refinitiv. Minimum 15 minutes delayed.